Avidity biosciences announces inducement grants under nasdaq listing rule 5635(c)(4)

San diego , jan. 8, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that on january 6, 2025, the human capital management committee of avidity's board of directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common stock and 40,000 restricted stock units ("rsus") to charles calderaro iii, under the avidity biosciences, inc. 2022 employment inducement incentive award plan (the "2022 inducement plan"), in connection with mr. calderaro's hiring and appointment as avidity's chief technical officer.
RNA Ratings Summary
RNA Quant Ranking